This grant supports investigator-initiated clinical trials to reduce cancer burden through early detection, prevention, and survivorship improvements.
Funder: National Institutes of Health
Due Dates: January 7, 2027 (Current closing date)
Funding Amounts: No budget cap; requests must reflect project needs; maximum project period of 5 years
Summary: Supports investigator-initiated clinical trials to reduce cancer burden through prevention, early detection, screening, healthcare delivery, survivorship, and quality-of-life improvements.
Key Information: NIH-defined clinical trials are required; cancer diagnosis and oncologic treatment trials are not supported.
The National Cancer Institute (NCI) offers this R01 program for investigator-initiated Phase 0–IV clinical trials aligned with its Division of Cancer Prevention or Division of Cancer Control and Population Sciences. Studies should reduce the burden of cancer and have potential to improve clinical practice or public health.
Relevant work includes cancer prevention and interception, screening, early detection biomarkers, behavioral interventions, cancer susceptibility, implementation science, healthcare delivery, survivorship, supportive and palliative care, and quality of life. Trials may address burdens experienced by patients, survivors, families, and caregivers. Applications may combine clinical trials with other research aims and include correlative laboratory or imaging endpoints. Observational-only studies and trials focused on cancer diagnosis or oncologic treatment are outside this program’s scope.